Sleep

New research uncovers unique brain abnormalities linked to sleep disorders and deprivation, revealing insights into emotional and cognitive impacts.

Q1 2025 sleep updates include FDA rejecting pitolisant NDA for idiopathic hypersomnia, iptacopan improving PNH fatigue, and more.

A narrative review reports the connection between allergies and sleep and available treatment options for both conditions.

Pitolisant was evaluated for the supplemental indication in the phase 3 INTUNE study, which did not meet its primary outcome of reducing excessive daytime sleepiness.

2 phase 3 trials show iptacopan improves fatigue, quality of life, and hematologic markers in C5i-experienced or -naive patients with paroxysmal nocturnal hemoglobinuria.

A collaborative approach to patient sleep health

Subjective poor sleep quality is tied to greater systolic blood pressure in adults ≤ 49 years with optimal sleep duration, compared with adults ≥ 50 years.

This Month in Review captures 7 sleep medicine news, including FDA updates, from December 2024.

To celebrate the close of 2024, we're recapping the 10 most popular approval articles across the HCPLive Network of brands.

From FDA approvals to updated guidelines, 2024 brought transformative advancements in sleep medicine, offering new hope for managing complex sleep disorders.

Tirzepatide's approval marks the first and only prescription medicine available for adults with moderate-to-severe obstructive sleep apnea and obesity.

A study showed parents of children with atopic dermatitis have an increased odds of taking medication to aid sleep.

In a recent study, the prevalence of RLS occurred in 42.9% of participants with depression.

The AASM has updated its RLS guidelines, now recommending against the standard use of dopamine agonists due to evidence of augmentation.

A new study showed patients with MASLD have fragmented nocturnal sleep with frequent awakenings per night and a session on healthy sleep habits did not improve sleep parameters.

Dreem 3S is the first sleep wearable with an FDA-authorized Predetermined Change Control Plan.

Following the publication of the new RLS recommendations, HCPLive spoke with John Winkelman, MD, PhD, chair of the AASM committee that revised the guidelines.

Following the approval of sodium oxybate for cataplexy in adults with cataplexy, the FDA approves this indication for the pediatric population.

Comorbid migraine and insomnia are linked to altered locus coeruleus connectivity, suggesting it is a biomarker for sleep disturbances and a potential therapeutic target.

This month in review highlights the top sleep stories in August, from sleep health in patients undergoing dialysis to the benefits of catching up on sleep.

People with the most weekend catch-up sleep had a 20% lower risk of heart disease, especially those who were sleep-deprived during the week.

Allegheny Health Network (AHN) implants innovative device to manage central sleep apnea in heart failure patients, reducing mortality rise and improving quality of life.

Nocturnal hypoxia may represent an additional modifiable risk factor for AMD, particularly its neovascular form.

Care for dialysis patients often focuses on kidney health, but experts and a patient stress the need for interdisciplinary care that also addresses sleep health.